• Explore /
  • Poster
  • / BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212).

BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212).

Abstract Poster

Authors

null

Ryan Bruce Corcoran

Massachusetts General Hospital Cancer Center, Boston, MA

Ryan Bruce Corcoran , Gerald Steven Falchook , Jeffrey R. Infante , Omid Hamid , Wells A. Messersmith , Eunice Lee Kwak , David P. Ryan , Razelle Kurzrock , Adrienne A Brenner , Jennifer Luan , Peng Sun , Alicia J Allred , Shonda M Little , Kiran Patel , Scott Kopetz , Alan Paul Venook

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

NCT01072175

Citation

J Clin Oncol 30, 2012 (suppl; abstr 3528)

DOI

10.1200/jco.2012.30.15_suppl.3528

Abstract #

3528

Poster Bd #

20

Abstract Disclosures

Similar Posters

First Author: Ryan Bruce Corcoran

First Author: Johanna C. Bendell

First Author: Manisha H. Shah

First Author: Amir Noeparast